Diagnosis and classification of ulcerative colitis

Autoimmunity Reviews

Volumn 13, Issue 4-5, 2014, Pages 463-466

  Conrad, Karsten ^a   Roggenbuck, Dirk ^b,c   Laass, Martin W ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b BRANDENBURG UNIVERSITY OF TECHNOLOGY   (Germany)

^c GA GENERIC ASSAYS GMBH   (Germany)

Author keywords

Crohn's disease; Diagnostic criteria; Inflammatory bowel diseases; Ulcerative colitis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CELL ANTIBODY; CYCLOSPORIN; GOBLET CELL ANTIBODY; MERCAPTOPURINE; MESALAZINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANAMNESIS; BLOOD TRANSFUSION; BLOODY DIARRHEA; CAUCASIAN; CLINICAL EVALUATION; CLINICAL FEATURE; COLITIS; COLON MUCOSA; COLON RESECTION; COLONOSCOPY; CROHN DISEASE; DIAGNOSTIC PROCEDURE; DIETARY INTAKE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DUODENOSCOPY; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GASTRODUODENOSCOPY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL RADIOGRAPHY; GOBLET CELL; HEREDITY; HISTOPATHOLOGY; HUMAN; ILEOCOLONOSCOPY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LABORATORY TEST; MEDICAL HISTORY; MODIFIED TRUELOVE AND WITTS SEVERITY INDEX; PANCOLITIS; PLASMACYTOSIS; PREVALENCE; PROCTITIS; PROCTOCOLECTOMY; PROGNOSIS; PUCAI SCORE; RATING SCALE; REMISSION; REVIEW; RISK FACTOR; SCORING SYSTEM; SEROLOGY; STEROID THERAPY; TOPICAL TREATMENT; ULCERATIVE COLITIS;

CROHN'S DISEASE; DIAGNOSTIC CRITERIA; INFLAMMATORY BOWEL DISEASES; ULCERATIVE COLITIS;

ANTIGENS; AUTOANTIBODIES; COLITIS, ULCERATIVE; COLONOSCOPY; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; HUMANS;

EID: 84896314215     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.01.028     Document Type: Review

References (28)

1. Ekbom A. The changing faces of Crohn's disease and ulcerative colitis. Inflammatory bowel disease: from bench to bedside 2003, 5-20. Kluwer Academic Publishers, Dordrecht/Boston/London. 2nd ed. S.R. Targan, F. Shanahan, L.C. Karp (Eds.).
2. Logan I., Bowlus C.L. The geoepidemiology of autoimmune intestinal disease. Autoimmun Rev 2010, 9:A372-A378.
3. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54.
4. Calkins B.M., Mendeloff A.I. Epidemiology of inflammatory bowel disease. Epidemiol Rev 1986, 8:60-91.
5. Hanauer S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006, 12:S3-S9.
6. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
7. Round J.L., Mazmanian S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009, 9:313-323.
8. Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
9. Brant S.R. Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis 2011, 17:1-5.
10. Probert C.S., Jayanthi V., Pinder D., Wicks A.C., Mayberry J.F. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut 1992, 33:687-693.
11. -/- mice. Nature 2012, 487:104-108.
12. Stange E.F., Travis S.P., Vermeire S., Reinisch W., Geboes K., Barakauskiene A., et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008, 2:1-23.
13. Lennard-Jones J.E. Classification of inflammatory bowel diseases. Scand J Gastroenterol 1989, 24:2-6.
14. Bousvaros A., Antonioli D.A., Colletti R.B., Dubinsky M.C., Glickman J.N., Gold B.D., et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007, 44:653-674.
15. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl. A):5-36.
16. Inflammatory Bowel Disease Working Group of ESPGHAN Inflammatory bowel disease in children and adolescents: recommendations for diagnosis - the Porto criteria. J Pediatr Gastroenterol Nutr 2005, 41:1-7.
17. Levine A., Griffiths A., Markowitz J., Wilson D.C., Turner D., Russell R.K., et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011, 17:1314-1321.
18. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
19. Magro F., Langner C., Driessen A., Ensari A., Geboes K., Mantzaris G.J., et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013, 7:827-851.
20. Conrad K., Schmechta H., Klafki A., Lobeck G., Uhlig H., Gerdi S., et al. Serological differentiation of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2002, 14:1-7.
21. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006, 52:171-181.
22. Conrad K., Bachmann M., Stöcker W. Anti-intestinal goblet cell antibodies. Autoantibodies 2006, 417-422. Elsevier. 2nd ed. Y. Shoenfeld, M.E. Gershwin, P.L. Meroni (Eds.).
23. Stinton L.M., Bentow C., Mahler M., Norman G.L., Eksteen B., Mason A.L., et al. PR3-ANCA as a promising biomarker for the diagnosis of primary sclerosing cholangitis (PSC). Infection, Tumors and Autoimmunity, Report on the 11th Dresden Symposium on Autoantibodies 2013, 249-250. K. Conrad, E.K.L. Chan, M.J. Fritzler, R.L. Humbel, P.L. Meroni, G. Steiner (Eds.).
24. Mahler M., Bogdanos D.P., Pavlidis P., Fritzler M.J., Csernok E., Damoiseaux J., et al. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta 2013, 424:267-273.
25. Turner D., Levine A., Escher J.C., Griffiths A.M., Russell R.K., Dignass A., et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012, 55:340-361.
26. Turner D., Otley A.R., Mack D., Hyams J., de Bruijne J., Uusoue K., et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007, 133:423-432.
27. Sutherland L., MacDonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, (2). [Art. No.: CD000543.pub2]. 10.1002/14651858.CD000543.pub2.
28. Van Limbergen J., Russell R.K., Drummond H.E., Aldhous M.C., Round N.K., Nimmo E.R., et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008, 135:1114-1122.